Panbela Therapeutics (PBLA) 10-Q2024 Q2 Quarterly report

Filed: 13 Aug 24, 5:08pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abstaining, assign, assigning, assignment, collateral, committee, committing, copyright, damage, DDW, deliberation, description, Difluoromethylornithine, Digestive, DNA, equivalent, foregoing, Gastric, immunostaining, Incidence, Latin, marker, mature, Maturity, member, owed, penalty, pending, percent, placebo, placement, policy, Premalignant, premium, prepay, priority, purport, qualified, Qualifying, relist, repayment, Robert, royalty, Schemel, secret, short, sought, subordinate, subordinated, subordination, text, Thousand, trademark, transfer, transferring, unchanged, uplisting, USWM, UWSM, vi, voting, week, xiii

Removed: Abraxane, APAC, care, compliance, consecutive, continued, counter, cured, Department, disruption, experience, February, foreseeable, Litigation, opening, procure, reflected, Reform, regain, reliant, requirement, supply, utilized

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated PBLA transcripts

PBLA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Susan Horvath, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)		the Quarterly Report on Form 10-Q of Panbela Therapeutics, Inc. for the quarter ended June 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)		the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Panbela Therapeutics, Inc.

Dated: August 13, 2024

	/s/ Susan Horvath
	Susan Horvath
	Chief Financial Officer
	(Principal Financial Officer and Principal
	Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.